Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Poland flag Poland · Delayed Price · Currency is PLN
82.40
+0.40 (0.49%)
Mar 2, 2026, 12:25 PM CET
72.38%
Market Cap 453.35M
Revenue (ttm) 7.57M
Net Income (ttm) -40.71M
Shares Out 5.53M
EPS (ttm) -7.69
PE Ratio n/a
Forward PE 189.60
Dividend n/a
Ex-Dividend Date n/a
Volume 4,542
Average Volume 9,479
Open 82.00
Previous Close 82.00
Day's Range 80.00 - 82.60
52-Week Range 31.20 - 86.00
Beta 0.71
RSI 56.36
Earnings Date Apr 2, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 91
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CTX
Full Company Profile

Financial Performance

In 2024, WSE:CTX's revenue was 15.83 million, an increase of 19.88% compared to the previous year's 13.20 million. Losses were -38.43 million, -45.56% less than in 2023.

Financial Statements

News

There is no news available yet.